BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 17088923)

  • 1. Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    Murthy PB; Sexton WJ
    J Urol; 2023 Nov; 210(5):726-727. PubMed ID: 37757487
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    Prasad SM
    J Urol; 2023 Dec; 210(6):840. PubMed ID: 37769639
    [No Abstract]   [Full Text] [Related]  

  • 3. Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group.
    Yuk HD; Kim JK; Jeong CW; Kwak C; Kim HH; Ku JH
    Biomed Res Int; 2018; 2018():9432606. PubMed ID: 30271788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incrusted cystitis after intravesical mitomycin C treatment.
    Llopis M; Moreno J; Botella R; Algado M
    Acta Urol Belg; 1993 Sep; 61(3):21-3. PubMed ID: 8256682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor.
    Onishi T; Sasaki T; Hoshina A; Yabana T
    Anticancer Res; 2011 Apr; 31(4):1471-4. PubMed ID: 21508405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
    Oosterlinck W
    Nat Clin Pract Urol; 2006 Nov; 3(11):582-3. PubMed ID: 17088923
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravesical mitomycin C for superficial transitional cell carcinoma.
    Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Calcified bladder lesions secondary to the instillation of mitomycin C].
    Megias Garrigós J; Pelluch Auladell A; Romero Pérez P; Fernandez García J; Gassó Matoses M; Sánchez Marcos M; Mira Llinarés A
    Arch Esp Urol; 1991 Nov; 44(9):1057-60. PubMed ID: 1807206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Papillary-like bladder calcifications following intravescical mitomycin C. A case report.
    Fiore AA; Iorio B; Vennarecci G; Venditti D; Cervelli V; Giudiceandrea F; Casciani CU
    Minerva Urol Nefrol; 1993 Dec; 45(4):171-3. PubMed ID: 8023227
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.